Thursday, October 12, 2017

Biogen and Roche on MS drug Ocrevus [ocrelizumab ]

From a post at Reuters :

U.S.-based Biogen is entitled to between 13.5 and 24 percent of U.S. sales and 3 percent of sales elsewhere from Roche’s new multiple sclerosis drug Ocrevus, whose annual revenue may hit $4 billion by 2022.

from Double Whammy for Roche

See also previous IPBiz post:

Lipoic acid and secondary progressive multiple sclerosis


Post a Comment

<< Home